A virus-based treatment for low-grade upper tract bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a low-grade (not high-grade) cancer in the upper urinary tract, confirmed by biopsy within the last 2 months.
- You have at least one small tumor (5 to 15 mm) above the point where the ureter meets the kidney, and it can be seen with a scope.
- You are willing to be followed for at least 18 months after your first dose.
- Your overall health is fairly good (ECOG score 2 or less, meaning you can care for yourself).
- Your kidney function is adequate (eGFR at least 45, or 60 for the first group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy pill, dabogratinib, for people with low-grade upper tract urothelial carcinoma (a type of cancer in the tubes that carry urine from kidneys to bladder). It may be an option if you have tumor tissue left after a biopsy and haven't had certain prior treatments.
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
This trial tests a new treatment combination before bladder removal surgery for muscle-invasive bladder cancer. It uses a special virus-delivered gene therapy (nadofaragene firadenovec) plus two chemotherapy drugs (cisplatin and gemcitabine) and an immunotherapy drug (durvalumab) to try to shrink the tumor and improve outcomes.
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Hear when a new Low-grade Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.